Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
Location: United States, California, San Diego
Employees: 501-1000
Total raised: $260M
Founded date: 2009
Investors 5
Date | Name | Website |
- | Aisling Ca... | aislingcap... |
- | Ally Bridg... | ally-bridg... |
- | Hercules C... | htgc.com |
- | ShareLink ... | sharelink-... |
- | Canaan Par... | canaan.com |
Funding Rounds 4
Date | Series | Amount | Investors |
08.10.2019 | - | $25M | - |
29.11.2016 | - | $75M | - |
03.05.2016 | - | $10M | - |
10.04.2016 | - | $150M | Ally Bridg... |
Mentions in press and media 19
Date | Title | Description | Source |
08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID... | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of ... | einpresswi... |
19.02.2023 | Sorrento Posts Form 8937 to Supplement its Previously Issued... | SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. SRNE "Sorrento"))... | einpresswi... |
25.03.2022 | Scilex Holding Company, a majority-owned subsidiary of Sorre... | PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-... | globenewsw... |
20.01.2022 | SORRENTO THERAPEUTICS ANNOUNCES COVISHIELD (STI-9167), A BRO... | SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento&q... | marketscre... |
16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi ... | By Jeff Craven Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the ... | endpts.com... |
09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven On March 11, the World Health Organization classified the Covid-19 outbreak as... | endpts.com... |
18.06.2019 | Sorrento Valley startup raises $3M following pitch competiti... | - | teal-ventu... |
22.08.2017 | Sorrento Therapeutics Invests In New Company, Celularity... | San Diego-based biopharmaceuticals developer Sorrento Therapeutics announced on Monday that it has i... | socaltech.... |
14.04.2017 | Sorrento drops 39% before Easter after shares offering | San Diego biotech Sorrento, which spent much of the last 12 months warring with its minority stakeho... | fiercebiot... |
16.03.2017 | Aerpio Pharmaceuticals Raises $40 Million | Aerpio Pharmaceuticals, Inc. (the “Company”), a biopharmaceuticalcompany focused on advancing first-... | ally-bridg... |
Show more